A phase Ib (NCT 05453903) clinical study explored the safety and efficacy of Bleximenib in combination with Venetoclax and Azacitidine in R/R AML patients with KMT2A rearrangements or NPM1 mutations [98]. This evidence concerns the gene NPM1 and acute myeloid leukemia.